Quantcast

Latest Transition Therapeutics Inc. Stories

2014-03-03 12:26:58

TORONTO, March 3, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI) (TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the 34(th) Annual Cowen & Co. Healthcare Conference on Tuesday, March 4th, 2014 at 10:00 a.m. Eastern Time at the Boston Marriott Copley Place Hotel in Boston, MA. About Transition Transition is a biopharmaceutical company, developing novel...

2014-02-28 08:25:07

-- All development and commercialization rights of ELND005 drug candidate have been transferred to an Irish-domiciled company ("Irish Subsidiary") -- Transition has acquired 100% of the common shares of Irish Subsidiary -- Irish Subsidiary will be responsible for the future development and commercialization of ELND005 for all disease indications -- Affiliates of Perrigo Company plc ("Perrigo") will...

2014-02-28 08:25:06

DUBLIN, Feb. 28, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) announced today that it entered into a series of agreements with existing collaboration partner, Transition Therapeutics Inc. (Nasdaq: TTHI), to progress the clinical development of ELND005 (Scyllo-inositol) in a number of important indications including Alzheimer's disease, Bipolar Disorder and Down Syndrome. As part of the transaction, Transition Therapeutics will acquire all of the shares of a wholly...

2014-02-12 16:26:40

TORONTO, Feb. 12, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH) (NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the three and six month periods ended December 31, 2013. Selected Highlights Highlights for the Company during the six month period ended December 31, 2013 and up to the date of this MD&A include...

2014-02-07 12:23:45

TORONTO, Feb. 7, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, February 12th, 2014 at 4:30 P.M. EST to discuss Second Quarter Fiscal 2014 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate...

2014-02-06 12:28:27

TORONTO, Feb. 6, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the 16(th) Annual BIO CEO & Investor Conference on Tuesday, February 11th, 2014 at 3:30 p.m. Eastern Time at the Waldorf Astoria in New York City. About Transition Transition is a biopharmaceutical company, developing novel therapeutics for...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related